Fundalysisby DARKHORSESTOCKS

Scheme

Nippon India Nifty Pharma ETF

Holds 20 companies worth ₹1,736 Cr in Sept 2026.

  • Fund house

    NipponThe fund house that runs this scheme.

  • AUM

    ₹1,736 CrNippon India Nifty Pharma ETF's AUM at the end of 30 Sept 2026, as AMFI reports it. Down 1.4% on Aug 2026, ₹1,761 Cr.

  • Largest holding

    Sun Pharmaceutical Ind LtdSun Pharmaceutical Ind Ltd is 19.5% of this scheme's NAV.

  • Fund manager

    Jitendra TolaniRuns it since 1 Feb 2025, as the fund house dates it.

Overview(8 Oct 2026)

Fund managers1

  1. Jitendra TolaniFund manager · Feb 2025 · 20y · MBA
  1. Himanshu MangeDec 2023 – Feb 2025

Key facts

Benchmark
Nifty Pharma TRI
Risk
Very High
Expense
Regular 0% · Direct 0.23%
Exit load
Nil
Started
2 Jul 2021
Minimum
In creation unit size of 75,000 units and in multiples thereafter However, in case of large investors, the execution value must be greater than Rs. 25 crores

Source.Its Scheme Summary Document as of 8 Oct 2026 at AMFI.

What changed(4 changes)

Oct 2026

1 change
  1. Expense ratio
    8 OctDirect 0.24% → 0.23%

Aug 2026

1 change
  1. Expense ratio
    23 AugDirect 0.21% → 0.24%

Feb 2025

2 changes
  1. Jitendra Tolani joined
    10 Febas fund manager
  2. Himanshu Mange left
    10 Febran it as fund manager from Dec 2023

Source.Its filings at NSE, since Aug 2024.

Fund managers over time(Dec 2023 – now)

  1. Jitendra Tolani
  2. Himanshu Mange
MainCoSlice202420252026
Fig. 1.Who ran it when: each manager from the date the fund house gives, or the first document listing them where it gives none, to when they left. A slice is part of it: overseas, gold and silver, or arbitrage.

Costs(Aug 2024 – Oct 2026)

Every change to the expense ratio, newest first.
3 changesRegularDirectΔ pt
8 Oct 20260.00%0.23%0.01
23 Aug 20260.00%0.24%0.03
20 Aug 20240.00%0.21%–
Direct plan, 8 Oct 2026
0.23%
Regular plan 0.00% · Exit load nil
Fig. 1.Total expense ratio a year, each plan's, as its Scheme Summary Documents state it, filing by filing at NSE. A change holds until the next.

Objective and risk(8 Oct 2026)

Objective

The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.

Risk, type and benchmark

Riskometer
Very High
At launch
Very High
Type
An open ended scheme replicating/ tracking NIFTY Pharma Index
Benchmark
Nifty Pharma TRI

Asset allocation it may hold% of NAV

  1. Securities constituting securities constituting Nifty Pharma Index
    Allowed95–100%
  2. Money Market Instruments including TriParty Repo on governement securities or T-Bills, cash & cash equivalents or Liquid Schemes
    Allowed0–5%Holds0.1%

Holds in Sept 2026.99.9% equity · 0.1% debt and cash

How to invest(8 Oct 2026)

Buying

To start
In creation unit size of 75,000 units and in multiples thereafter However, in case of large investors, the execution value must be greater than Rs. 25 crores

Selling and switching

To redeem
In creation unit size of 75,000 units and in multiples thereafter However, in case of large investors, the execution value must be greater than Rs. 25 crores units
Switch minimum
In creation unit size of 75,000 units and in multiples thereafter However, in case of large investors, the execution value must be greater than Rs. 25 crores units

Scheme details(8 Oct 2026)

What it is

Offer
21 Jun 2021 to 28 Jun 2021
Started
2 Jul 2021
Reopened
7 Jul 2021
Face value
Rs.10/- per unit
Listed
NSE

How it is run

Swing pricing
No
Side-pocketing
No
Custodian
Deutsche Bank A.G.
Auditor
Walker Chandiok & Co LLP
Registrar
KFin Technologies Limited